Is Bronchogen FDA approved?
No. This profile records Bronchogen as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
THE LUNG RESTORER
AEDL peptide
Bronchogen is a short peptide (AEDL) from the Khavinson family designed to support respiratory health. It works by modifying gene expression in lung tissue, helping restore the epithelial lining, reduce inflammation, and improve surfactant production. It's studied for COPD, chronic bronchitis, and age-related lung decline.
Not FDA approved · research use only
Reviewed by our clinical team
1 research sources
May 8, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records Bronchogen as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: 750 mcg daily.
Schedule: daily. Cycle: 4 weeks on, 8 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Binds DNA to modify gene expression in lung tissue
Reduces pro-inflammatory cytokines (TNF-α, IL-6)
Restores bronchial lining and mucosal barrier function
Enhances lung surfactant for better gas exchange
The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.